Howard Lee

Howard Lee currently works at TAHO Pharmaceuticals Ltd., as Chairman & Chief Executive Officer from 2020, Transwell Biotech Co. Ltd., as Chairman, Waterstone Pharmaceuticals, Inc., as Director, CryptoComm Partners LP, as Director, Amphastar Pharmaceuticals, Inc., as Independent Director from 2007, Sunko Ink Co., Ltd., as Independent Director from 2016, Genovate Biotechnology Co., Ltd., as Independent Director from 2020, Development Center for Biotechnology, as Director, Easywell Biomedicals, Inc., as Director, TaiMed Biologics, Inc., as Independent Director from 2017, Epoch Foundation, as Director-Supervisory Board, Association of Technology Managers In Taiwan, as Director-Supervisory Board, and Magnifica, Inc., as Director.
Dr. Lee also formerly worked at CDIB Biotech USA Investment Co. Ltd., as President & Chief Executive Officer from 2000 to 2006, International Medication Systems Ltd., as Director from 1998 to 2002, Optimer Pharmaceuticals LLC, as Director, AVIVA Biosciences Corp., as Director, InnoPharmax, Inc., as Director, OBI Pharma, Inc., as Director, Silver Biotech Management, Inc., as Managing Director from 2006 to 2009, Kuo Ching Chemical Co., Ltd., as Independent Director from 2011 to 2018, CapsoVision, Inc., as Director, CDIB Capital Group, as Vice President from 1995 to 2006, UniMed Venture Management, Inc., as Chief Investment Officer from 2009 to 2010, and The CID Group (China), as Partner from 2012 to 2020.
Dr. Lee received his graduate degree in 1990 and doctorate degree in 1990 from the University of Southern California and undergraduate degree from Fu Jen Catholic University.